The Logan Permea-Plate (PermeaPad® 96-well biomimetic membrane microplate system) is designed for rapid screening of new drug lead compounds, high-throughput passive diffusion-permeability (HTS) and in vitro-in vivo correlation (IVIVC) prediction of poorly soluble drugs (BCS Class II/IV), self-microemulsion delivery systems (SMEDDS), amorphous solid dispersions (ASD), and various oral formulations. This system fully complies with ANSI/SLAS microplate standards and seamlessly integrates automated liquid handling workstations with microplate analyzers, eliminating the time-consuming and cumbersome process of traditional Caco-2 cell culture (up to 21 days). It provides a highly reproducible and standardized penetration assessment platform for early-stage drug development and prescription optimization.

I. Patented Biomimetic Lipid Barrier: Utilizing a high-density lecithin (Phospholipid S-100) biomimetic membrane, it is ready to use immediately without hydrolysis. It is resistant to physiological media, biologically related media (FaSSGF/FaSSIF/FeSSIF), and surfactants (SDS/Tween/TPGS/DMSO) at pH 1.0–9.0, exhibiting a stable structure that does not detach.

II. 96-Well Standard Specification and Fully Automated Integration: ANSI/SLAS compliant double-layer microplate design, capable of testing 96 samples per batch; standard anti-evaporation cap; highly compatible with automated pipetting robots, temperature-controlled shaking chambers, and sampling workstations, significantly reducing human error between wells.

III. Superior IVIVC Prediction and Diverse Detection (IVIVC & Analytical Connectivity): With polarity-independent diffusion characteristics, it accurately measures cumulative amount (Q), throughput (J), and apparent penetration coefficient (Papp), with reproducibility (%RSD) superior to traditional cells and PAMPA; it can be directly connected to a microplate reader (UV/fluorescence) or a 96-well HPLC/UPLC/LC-MS/MS mass spectrometry system.

Product Introduction

• Compliant with international standards and featuring patented biomimetic barrier technology (Regulatory Standards & Ready-to-Use Biomimetic Barrier Technology)

  • Fully compliant with international ANSI/SLAS microplate standards, it is designed for rapid screening of new drug lead compounds, poorly soluble drugs (BCS Class II/IV), self-microemulsifying delivery systems (SMEDDS/SNEDDS), and amorphous solid dispersions (ASD).

  • Using a patented multilayer high-density lecithin (Phospholipid S-100) biomimetic lipid matrix, it is pre-filled in the bottom of the microwell tray at the factory, ready to use without hydration or activation, completely eliminating the time-consuming and cumbersome process of traditional Caco-2 cell culture that lasts up to 21 days, and significantly shortening the research and development cycle.

• Wide pH tolerance and excellent compatibility with biorelevant media.

  • It possesses extremely wide chemical tolerance and stability (tolerance range of pH 1.0 to 10.0), and can accurately simulate the gradual change of the complete physiological environment of the human body from the stomach to the intestines.

  • The membrane structure possesses extreme mechanical and chemical stability, and can completely withstand biological media such as FaSSGF, FaSSIF, and FeSSIF, as well as high concentrations of surfactants/solvents (SDS, Tween 80, TPGS, DMSO, PEG). There is no lipid leakage or dissolution during testing, and the stability test time can be up to 24 hours or more.

• Seamless integration of high-throughput 96-well format with fully automated workstations.

  • It adopts a standard double-layer microporous structure design, including an upper pre-installed biomimetic membrane Donor Plate, a lower Receiver Plate, and a dedicated low-evaporation lid, which can simultaneously perform 96 sets of penetration tests in a single batch.

  • The donor end (100–200 µL) and receiver end (250–350 µL) are designed with micro-volume to effectively save precious API samples; it is highly compatible with mainstream automated liquid handling workstations, temperature-controlled shaking incubators and Logan automated sampling workstations, significantly reducing well-to-well human operation variation.

• Superior IVIVC Prediction & Multi-Parameter Kinetics

  • It possesses excellent polarity-independent diffusion properties, which can simultaneously and accurately assess the passive diffusion and absorption behavior of hydrophilic, lipophilic, and amphoteric molecules.

  • It supports freely customizable sampling intervals and can accurately measure cumulative penetration ($Q$), penetration flux ($J$), apparent permeability ($P_{\text{app}}$), and drug recovery rate (Drug Recovery %). The well-to-well and batch-to-batch reproducibility (%RSD) is far superior to traditional PAMPA and cell models.

• Versatile Analytical Detection & Comprehensive Drug Validation Support

  • The sample plate has high optical transmittance and low adsorption characteristics, and can be directly connected to a microplate reader (UV/Vis, fluorescence spectroscopy), or can be directly placed into a 96-well autosampler plate for high-sensitivity mass spectrometry quantitative analysis by HPLC, UPLC or LC-MS/MS.

  • It possesses a complete model drug validation database and has completed detailed penetration testing of drugs including Acyclovir, Antipyrine, Atenolol, Caffeine, Carbamazepine, Donepezil HCl, Enalapril, Hydrocortisone, Ibuprofen, Metoprolol, Nadolol, Naproxen, Norfloxacin, Paracetamol, Sulpiride, Theobromine, Theophylline, Terbutaline, Verapamil HCl, and fluorescent markers (Calcein, Lucifer Yellow).